ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results

Biotech firm aTyr Pharma Inc. ATYR plummeted over 81% at last check on Monday, with a session volume of 34.7 million compared to the average volume of 4.83 million as per data from Benzinga Pro.In other words, many investors are selling. Why? The company’s Phase 3 trial results of its drug efzofitimod for pulmonary sarcoidosis, and the trial failed its primary endpoint.The trial involved 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease. ATyr will reportedly engage the Feder ...